Wells Fargo Maintains Medtronic(MDT.US) With Buy Rating, Maintains Target Price $106
Wells Fargo Remains a Buy on Medtronic (MDT)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Medtronic (MDT), Harmony Biosciences Holdings (HRMY) and Keros Therapeutics (KROS)
Barclays Maintains Medtronic(MDT.US) With Buy Rating, Maintains Target Price $105
Barclays Sticks to Their Buy Rating for Medtronic (MDT)
Truist Securities Maintains Hold on Medtronic, Raises Price Target to $90
Medtronic Analyst Ratings
Truist Financial Maintains Medtronic(MDT.US) With Hold Rating, Announces Target Price $90
Barclays Maintains Medtronic(MDT.US) With Buy Rating, Raises Target Price to $105
Barclays Maintains Overweight on Medtronic, Raises Price Target to $105
A Quick Look at Today's Ratings for Medtronic(MDT.US), With a Forecast Between $90 to $106
Medtronic Hold Rating Justified by Balanced Growth and Conservative Outlook
Argus Research Releases a Buy Rating on Medtronic (MDT)
A Quick Look at Today's Ratings for Medtronic(MDT.US), With a Forecast Between $87 to $106
Analysts Offer Insights on Healthcare Companies: MacroGenics (MGNX) and Medtronic (MDT)
Wells Fargo Adjusts Price Target on Medtronic to $106 From $105, Maintains Overweight
Analysts Conflicted on These Healthcare Names: Medtronic (MDT) and Schrodinger (SDGR)
Stifel Maintains Hold on Medtronic, Raises Price Target to $87
Medtronic Financial Analysis: A Balanced Hold Rating Amid Growth and Uncertainty
Medtronic Analyst Ratings